We conducted the largest study comparing autologous hematopoietic cell transplantation with allogeneic hematopoietic cell transplantation in grades 1 and 2 follicular lymphoma in rituximab era.
In follicular lymphoma patients surviving 2 years after hematopoietic cell transplantation, allografting provided an overall survival benefit.
Rituximab resistance does not predict hematopoietic cell transplantation outcomes.
Overall survival was better in those with hematopoietic cell transplantation performed from 2008 onward.
Second hematological malignancies develop only after a autologous hematopoietic cell transplantation.